Torrent Pharma - Curatio Acquisition Strengthens Derma Portfolio
While the acquisition will help with the company’s portfolio expansion and widen its reach to dermatologists/paediatricians, the deal valuation is...
122 Views
US drags 3QFY22 earnings; inspections key to a revival
TRP's 3QFY22 performance missed our estimate. The US Generics business remains the major drag on overall performance, with a lack of new...
272 Views
Torrent Pharmaceuticals: Branded Business Solid but Generics Stumble
Incorporated in 1959, Torrent has a strong presence in domestic and semi-regulated markets and a growing presence in regulated markets.
153 Views
Torrent Pharma (Results Review Q2FY22): Tepid quarter; steady outlook. Maintain ADD
The company repaid debt of INR4.9bn in H1 and is on track to reduce it by ~INR10bn in FY22. We reduce our EBITDA estimates by 4-5% for FY22-23e and...
67 Views
Torrent Pharmaceuticals: India Growth Drives Steady Numbers
A strong growth track in top brands, measured new launches (including innovative launches) besides strong balance sheet and comfort on corporate...
100 Views